Antiapoptotic Bcl-2 protein as a potential target for cancer therapy: A mini review

References

• Adams JM, Cory S. 1998. The Bcl-2 protein family: arbiters of cell survival. Science. 281:1322–1326.
   PubMed Web of Science ®Google Scholar
• Akar U, Chaves-Reyez A, Barria M, Tari A, Sanguino A, Kondo Y, et al. 2008. Silencing of Bcl-2 expression by small interfering RNA induces autophagic cell death in MCF-7 breast cancer cells. Autophagy. 4:669.
   PubMed Web of Science ®Google Scholar
• Badros AZ, Goloubeva O, Rapoport AP, Ratterree B, Gahres N, Meisenberg B, et al. 2005. Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients. J Clin Oncol. 23:4089–4099.
   PubMed Web of Science ®Google Scholar
• Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, et al. 2006. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol. 24:4738–4745.
   PubMed Web of Science ®Google Scholar
• Benjaminsen RV, Mattebjerg MA, Henriksen JR, Moghimi SM, Andresen TL. 2013. The possible “proton sponge” effect of polyethylenimine (PEI) does not include change in lysosomal pH. Mol Ther. 21:149–157.
   PubMed Web of Science ®Google Scholar
• Brown JM, Attardi LD. 2005. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer. 5:231–237.
   PubMed Web of Science ®Google Scholar
• Campos L, Rouault J-P, Sabido O, Oriol P, Roubi N, Vasselon C, et al. 1993. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood. 81:3091–3096.
   PubMed Web of Science ®Google Scholar
• Chauhan D, Velankar M, Brahmandam M, Hideshima T, Podar K, Richardson P, et al. 2006. A novel Bcl-2/Bcl-XL/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene. 26: 2374–2380.
   PubMed Web of Science ®Google Scholar
• Corey DR. 2007. Chemical modification: the key to clinical application of RNA interference? J clin Invest. 117:3615–3622.
   PubMed Web of Science ®Google Scholar
• Cory S, Vaux DL, Strasser A, Harris AW, Adams JM. 1999. Insights from Bcl-2 and Myc: malignancy involves abrogation of apoptosis as well as sustained proliferation. Cancer Res. 59:1685s–1692s.
   PubMed Web of Science ®Google Scholar
• Cotter F, Corbo M, Raynaud F, Orr R, Pocock C, Bryan B, et al. 1996. Bcl-2 antisense therapy in lymphoma: in vitro and in vivo mechanisms, efficacy, pharmacokinetic and toxicity studies. Ann Oncol. 7:327.
   PubMed Web of Science ®Google Scholar
• Davis JM, Navolanic PM, Weinstein-Oppenheimer CR, Steelman LS, Hu W, et al. 2003. Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance. Clin Cancer Res. 9:1161–1170.
   PubMed Web of Science ®Google Scholar
• Del Bufalo D, Biroccio A, Leonetti C, Zupi G. 1997. Bcl-2 overexpression enhances the metastatic potential of a human breast cancer line. FASEB J. 11:947–953.
   PubMed Web of Science ®Google Scholar
• Delia D, Aiello A, Formelli F, Fontanella E, Costa A, Miyashita T, et al. 1995. Regulation of apoptosis induced by the retinoid N-(4-hydroxyphenyl) retinamide and effect of deregulated bcl-2. Blood. 85: 359–367.
   PubMed Web of Science ®Google Scholar
• Dole M, Nuñez G, Merchant AK, Maybaum J, Rode CK, Bloch CA, Castle VP. 1994. Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res. 54:3253–3259.
   PubMed Web of Science ®Google Scholar
• Draz MS, Fang BA, Zhang P, Hu Z, Gu S, Weng KC, et al. 2014. Nanoparticle-mediated systemic delivery of siRNA for treatment of cancers and viral infections. Theranostics. 4:872–892.
   PubMed Web of Science ®Google Scholar
• El-Aneed A. 2004. An overview of current delivery systems in cancer gene therapy. J Control Release. 94:1–14.
   PubMed Web of Science ®Google Scholar
• Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. 2001. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 411:494–498.
   PubMed Web of Science ®Google Scholar
• Elmore S. 2007. Apoptosis: a review of programmed cell death. Toxicol Pathol. 35:495–516.
   PubMed Web of Science ®Google Scholar
• Felnerova D, Viret J-Fo, Glück R, Moser C. 2004. Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr Opin Biotechnol. 15:518–529.
   PubMed Web of Science ®Google Scholar
• Feng LF, Zhong M, Lei XY, Zhu BY, Tang SS, Liao DF. 2006. Bcl-2 siRNA induced apoptosis and increased sensitivity to 5-fluorouracil and HCPT in HepG2 cells. J Drug Target. 14:21–26.
   PubMed Web of Science ®Google Scholar
• Fesik SW. 2005. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer. 5:876–885.
   PubMed Web of Science ®Google Scholar
• Figuerola A, Di Corato R, Manna L, Pellegrino T. 2010. From iron oxide nanoparticles towards advanced iron-based inorganic materials designed for biomedical applications. Pharmacol Res. 62:126–143.
   PubMed Web of Science ®Google Scholar
• Futami T, Miyagishi M, Seki M, Taira K. 2002. Induction of apoptosis in HeLa cells with siRNA expression vector targeted against bcl-2. Nucl Acids Symp Ser (Oxford Univ Press). 251–252.
   Google Scholar
• George J, Banik NL, Ray Sk. 2009a. Bcl-2 siRNA augments taxol mediated apoptotic death in human glioblastoma U138MG and U251MG cells. Neurochem Res. 34:66–78.
   PubMed Web of Science ®Google Scholar
• George J, Banik NL, Ray SK. 2009b. Combination of taxol and Bcl‐2 siRNA induces apoptosis in human glioblastoma cells and inhibits invasion, angiogenesis and tumour growth. J Cell Mol Med. 13:4205–4218.
   PubMed Web of Science ®Google Scholar
• Gobé G, Rubin M, Williams G, Sawczuk I, Buttyan R. 2002. Apoptosis and expression of Bcl-2, Bcl-XL, and Bax in renal cell carcinomas. Cancer Invest. 20:324–332.
   PubMed Web of Science ®Google Scholar
• Hao J-H, Gu Q-L, Liu B-Y, Li J-F, Chen X-H, Ji Y-B, et al. 2007. Inhibition of the proliferation of human gastric cancer cells SGC-7901 in vitro and in vivo using Bcl-2 siRNA. Chin Med J-(Engl). 120:2105.
   PubMed Web of Science ®Google Scholar
• Heiser D, Labi V, Erlacher M, Villunger A. 2004. The Bcl-2 protein family and its role in the development of neoplastic disease. Exp Gerontol. 39:1125–1135.
   PubMed Web of Science ®Google Scholar
• Hetts SW. 1998. To die or not to die: an overview of apoptosis and its role in disease. JAMA. 279:300–307.
   PubMed Web of Science ®Google Scholar
• Hoare TR, Kohane DS. 2008. Hydrogels in drug delivery: progress and challenges. Polymer. 49:1993–2007.
   Web of Science ®Google Scholar
• Hockenbery D, Nuñez G, Milliman C, Schreiber RD, Korsmeyer SJ. 1990. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 348:334–6.
   PubMed Web of Science ®Google Scholar
• Hockenbery DM. 1994. Bcl-2 in cancer, development and apoptosis. J Cell Sci Suppl. 18:51–55.
   PubMedGoogle Scholar
• Holle L, Hicks L, Song W, Holle E, Wagner T, Yu X. 2004. Bcl-2 targeting siRNA expressed by a T7 vector system inhibits human tumor cell growth in vitro. Int J Oncol. 24:615–621.
   PubMed Web of Science ®Google Scholar
• Joensuu H, Pylkkänen L, Toikkanen S. 1994. Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol. 145:1191.
   PubMed Web of Science ®Google Scholar
• Johnstone RW, Ruefli AA, Lowe SW. 2002. Apoptosis: a link between cancer genetics and chemotherapy. Cell. 108:153–164.
   PubMed Web of Science ®Google Scholar
• Kang MH, Reynolds CP. 2009. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res. 15: 1126–1132.
   PubMed Web of Science ®Google Scholar
• Khan S, Maududi T, Barton K, Ayers J, Alkan S. 2004. Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma. Br J Haematol. 125:156–161.
   PubMed Web of Science ®Google Scholar
• Kichler A, Mason AJ, Bechinger B. 2006. Cationic amphipathic histidine-rich peptides for gene delivery. Biochim Biophys Acta. 1758:301–307.
   PubMed Web of Science ®Google Scholar
• Kim HK, Davaa E, Myung CS, Park JS. 2010. Enhanced siRNA delivery using cationic liposomes with new polyarginine-conjugated PEG-lipid. Int J Pharm. 392:141–147.
   PubMed Web of Science ®Google Scholar
• Kim R, Emi M, Tanabe K, Toge T. 2004. Therapeutic potential of antisense Bcl‐2 as a chemosensitizer for cancer therapy. Cancer. 101:2491–2502.
   PubMed Web of Science ®Google Scholar
• Kitada S, Kress CL, Krajewska M, Jia L, Pellecchia M, Reed Jc. 2008. Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2–transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048). Blood. 111: 3211–3219.
   PubMed Web of Science ®Google Scholar
• Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo Pp, Kitada S, et al. 2006. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer cell. 10:375–388.
   PubMed Web of Science ®Google Scholar
• Kroemer G. 1997. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med. 3:614–620.
   PubMed Web of Science ®Google Scholar
• Kumar M, Singh G, Sharma S, Gupta D, Bansal V, Arora V, et al. 2014. Intracellular delivery of peptide cargos using iron oxide based nanoparticles: studies on antitumor efficacy of BCL-2 converting peptide, NuBCP-9. Nanoscale. 1–15.
   Web of Science ®Google Scholar
• Kunze D, Wuttig D, Fuessel S, Kraemer K, Kotzsch M, Meye A, et al. 2008. Multitarget siRNA inhibition of antiapoptotic genes (XIAP, BCL2, BCL-XL) in bladder cancer cells. Anticancer Res. 28: 2259–2263.
   PubMed Web of Science ®Google Scholar
• Kurreck J. 2003. Antisense technologies. Eur J Biochem. 270:1628–1644.
   PubMedGoogle Scholar
• Leber B, Geng F, Kale J, Andrews DW. 2010. Drugs targeting Bcl-2 family members as an emerging strategy in cancer. Exp Rev Mol Med. 12:e28.
   PubMed Web of Science ®Google Scholar
• Leskov I, Pallasch C, Drake A, Iliopoulou B, Souza A, Shen C, et al. 2012. Rapid generation of human B-cell lymphomas via combined expression of Myc and Bcl2 and their use as a preclinical model for biological therapies. Oncogene. 32:1066–1072.
   PubMed Web of Science ®Google Scholar
• Lollo CP, Banaszczyk MG, Mullen PM, Coffin CC, Wu D, Carlo AT, et al. 2002. Poly-L-Lysine-Based Gene Delivery Systems. Gene therapy protocols. New York: Springer, pp. 1–13.
   Google Scholar
• Lorenz H, Herrmann M, Winkler T, Gaipl U, Kalden J. 2000. Role of apoptosis in autoimmunity. Apoptosis. 5:443–449.
   PubMed Web of Science ®Google Scholar
• Lowe SW, Lin AW. 2000. Apoptosis in cancer. Carcinogenesis. 21: 485–495.
   PubMed Web of Science ®Google Scholar
• Lytton-Jean AKR, Langer R, Anderson DG. 2011. Five years of siRNA delivery: spotlight on gold nanoparticles. Small. 7:1932–1937.
   PubMed Web of Science ®Google Scholar
• Ma Z, Li J, He F, Wilson A, Pitt B, Li S. 2005. Cationic lipids enhance siRNA-mediated interferon response in mice. Biochem Biophys Res Commun. 330:755–759.
   PubMed Web of Science ®Google Scholar
• MacVicar G, Kuzel T, Curti B, Poiesz B, Somer B, Greco F, et al. 2008.An open-label, multicenter, phase I/II study of AT-101 in combination with docetaxel (D), prednisone (P) in men with hormone refractory prostate cancer (HRPC). J Clin Oncol (Meeting Abstracts). 16043.
   Google Scholar
• Manero F, Gautier F, Gallenne T, Cauquil N, Grée D, Cartron P-F, et al. 2006. The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death. Cancer Res. 66:2757–2764.
   PubMed Web of Science ®Google Scholar
• Marcucci G, Byrd JC, Dai G, Klisovic MI, Kourlas PJ, Young DC, et al. 2003. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood. 101:425–432.
   PubMed Web of Science ®Google Scholar
• Marzo I, Naval J. 2008. Bcl-2 family members as molecular targets in cancer therapy. Biochem Pharmacol. 76:939–946.
   PubMed Web of Science ®Google Scholar
• Mattson MP. 2000. Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol. 1:120–130.
   PubMed Web of Science ®Google Scholar
• McDonnell TJ, Deane N, Platt FM, Nunez G, Jaeger U, Mckearn JP, Korsmeyer SJ. 1989. Bcl-2-Immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation . Cell. 57:79–88.
   PubMed Web of Science ®Google Scholar
• Medicine, UNLO Genetic Home Reference [Online]. 2014. Available: http://ghr.nlm.nih.gov/gene/BCL2 [Accessed 10th October 2014].
   Google Scholar
• Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, Kamidono S. 1999. Overexpression of Bcl-2 enhances metastatic potential of human bladder cancer cells. Br J Cancer. 79:1651.
   PubMed Web of Science ®Google Scholar
• Nakase M, Inui M, Okumura K, Kamei T, Nakamura S, Tagawa T. 2005. p53 gene therapy of human osteosarcoma using a transferrin- modified cationic liposome. Mol Cancer Ther. 4:625–631.
   PubMed Web of Science ®Google Scholar
• Ocker M, Neureiter D, Lueders M, Zopf S, Ganslmayer M, Hahn E, et al. 2005. Variants of bcl-2 specific siRNA for silencing antiapoptotic bcl-2 in pancreatic cancer. Gut. 54:1298–1308.
   PubMed Web of Science ®Google Scholar
• Pan H, Yin C, VAN Dyke T. 1997. Apoptosis and cancer mechanisms. Cancer Surv. 29:305.
   PubMedGoogle Scholar
• Pro B, Leber B, Smith M, Fayad L, Romaguera J, Hagemeister F, et al. 2008. Phase II multicenter study of oblimersen sodium, a Bcl‐2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B‐cell non‐Hodgkin lymphoma. Br J Haematol. 143:355–360.
   PubMed Web of Science ®Google Scholar
• Raffo AJ, Perlman H, Chen M-W, Day ML, Streitman JS, Buttyan R. 1995. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res. 55:4438–4445.
   PubMed Web of Science ®Google Scholar
• Raynaud FI, Orr RM, Goddard PM, Lacey HA, Lancashire H, Judson IR, et al. 1997. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice. J Pharmacol Exp Ther. 281:420–427.
   PubMed Web of Science ®Google Scholar
• Re R. 2000. The application of antisense technology to medicine. Ochsner J. 2:233–236.
   PubMedGoogle Scholar
• Read ML, Dash PR, Clark A, Howard KA, Oupicky D, Toncheva V, et al. 2000. Physicochemical and biological characterisation of an antisense oligonucleotide targeted against the bcl-2 mRNA complexed with cationicâhydrophilic copolymers. Eur J Pharm Sci. 10: 169–177.
   PubMed Web of Science ®Google Scholar
• Reed JC. 1999. Dysregulation of apoptosis in cancer. J Clin Oncol. 17:2941–2941.
   PubMed Web of Science ®Google Scholar
• Reed JC, Cuddy M, Slabiak T, Croce CM, Nowell PC. 1988. Oncogenic potential of bcl.-2 demonstrated by gene transfer. Nature. 336: 259–261.
   PubMed Web of Science ®Google Scholar
• Reed JC, Haldar S, Croce C, Cuddy M. 1990. Complementation by BCL2 and C-HA-RAS oncogenes in malignant transformation of rat embryo fibroblasts. Mol Cell Biol. 10:4370–4374.
   PubMed Web of Science ®Google Scholar
• Rudin C, Otterson G, Mauer A, Villalona-Calero M, Tomek R, Prange B, et al. 2002. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann Oncol. 13:539–545.
   PubMed Web of Science ®Google Scholar
• Rudin CM, Kozloff M, Hoffman PC, Edelman MJ, Karnauskas R, Tomek R, et al. 2004. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J Clin Oncol. 22:1110–1117.
   PubMed Web of Science ®Google Scholar
• Rudin CM, Salgia R, Wang X, Hodgson LD, Masters GA, Green M, Vokes EE. 2008. Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol. 26:870–876.
   PubMed Web of Science ®Google Scholar
• Saad M, Garbuzenko OB, Minko T. 2008.Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. Nanomedicine (Lond). 3: 761–776.
   Google Scholar
• Sartorius UA, Krammer PH. 2002. Upregulation of bcl‐2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer. 97:584–592.
   PubMed Web of Science ®Google Scholar
• Schmitt CA, Rosenthal CT, Lowe SW. 2000. Genetic analysis of chemoresistance in primary murine lymphomas. Nat Med. 6:1029–1035.
   PubMed Web of Science ®Google Scholar
• Shen M, Gong F, Pang P, Zhu K, Meng X, Wu C, et al. 2012. An MRI-visible non-viral vector for targeted Bcl-2 siRNA delivery to neuroblastoma. Int J Nanomed. 7:3319.
   PubMed Web of Science ®Google Scholar
• Shen M, Gong F, Pang P, Zhu K, Meng X, Wu C, et al. 2013. An MRI-visible non-viral vector for targeted Bcl-2 siRNA delivery to neuroblastoma. Int J Nanomed. 7:3319–3332.
   Web of Science ®Google Scholar
• Shim MS, Kwon YJ. 2010. Efficient and targeted delivery of siRNA in vivo. FEBS J. 277:4814–4827.
   PubMed Web of Science ®Google Scholar
• Sierra A, Castellsague X, Tortola S, Escobedo A, Lloveras B, Peinado MA, et al. 1996. Apoptosis loss and bcl-2 expression: key determinants of lymph node metastases in T1 breast cancer. Clin Cancer Res. 2:1887–1894.
   PubMed Web of Science ®Google Scholar
• Sinicrope FA, Penington RC, Tang XM. 2004. Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis Is Inhibited by Bcl-2 but Restored by the Small Molecule Bcl-2 Inhibitor, HA 14-1, in Human Colon Cancer Cells. Clin Cancer Res. 10:8284–8292.
   PubMed Web of Science ®Google Scholar
• Song T, Chang X, Zhang Z, Liu Y, Shen X. 2012. S1, a novel pan-BH3 mimetic, induces apoptosis in Mcl-1-overexpressing cells through Bak. J Pharmacol Sci. 119:330–340.
   PubMed Web of Science ®Google Scholar
• Sonoke S, Ueda T, Fujiwara K, Kuwabara K, Yano J. 2011. Galactose-modified cationic liposomes as a liver-targeting delivery system for small interfering RNA. Biol Pharm Bull. 34:1338–1342.
   PubMed Web of Science ®Google Scholar
• Strasser A, Harris AW, Bath Ml, Cory S. 1990. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature. 348:331–333.
   PubMed Web of Science ®Google Scholar
• Tahir SK, Yang X, Anderson MG, Morgan-Lappe SE, Sarthy AV, Chen J, et al. 2007. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res. 67:1176–1183.
   PubMed Web of Science ®Google Scholar
• Thompson CB. 1995. Apoptosis in the pathogenesis and treatment of disease. Science. 267:1456–1462.
   PubMed Web of Science ®Google Scholar
• Tolcher AW. 2001. Preliminary phase I results of G3139 ( bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer. Semin Oncol. 28:67–70.
   PubMed Web of Science ®Google Scholar
• Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, et al. 2008. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68:3421–3428.
   PubMed Web of Science ®Google Scholar
• Vaux DL, Cory S, Adams JM. 1988. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature (London). 335:440–442.
   PubMed Web of Science ®Google Scholar
• Veis DJ, Sorenson CM, Shutter JR, Korsmeyer SJ. 1993. Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell. 75:229–240.
   PubMed Web of Science ®Google Scholar
• Verdurmen WPR, Brock R. 2011. Biological responses towards cationic peptides and drug carriers. Trends Pharmacol Sci. 32:116–124.
   PubMed Web of Science ®Google Scholar
• Wacheck V, Losert D, Günsberg P, Vornlocher H-P, Hadwiger P, Geick A, et al. 2003. Small interfering RNA targeting bcl-2 sensitizes malignant melanoma. Oligonucleotides. 13:393–400.
   PubMedGoogle Scholar
• Walther W , Stein U. 2000. Viral vectors for gene transfer. Drugs. 60: 249–271.
   PubMed Web of Science ®Google Scholar
• Wang S, Yang D, Lippman ME. 2003. Targeting Bcl-2, Bcl-XL with nonpeptidic small-molecule antagonists. Seminars Oncol (Elsevier). 30:133–142.
   Google Scholar
• Warmann SW, Frank H, Heitmann H, Ruck P, Herberts T, Seitz G, Fuchs J. 2008. Bcl-2 gene silencing in pediatric epithelial liver tumors. J Surg Res. 144:43–48.
   PubMed Web of Science ®Google Scholar
• Waters JS, Webb A, Cunningham D, Clarke PA, Raynaud F, Di Stefano F, Cotter Fe. 2000. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol. 18:1812–1823.
   PubMed Web of Science ®Google Scholar
• Webb A, Cunningham D, Cotter F, Clarke P, Di Stefano F, Ross P, et al. 1997. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma . Lancet. 349:1137–1141.
   PubMed Web of Science ®Google Scholar
• Wei J, Kitada S, Rega MF, Stebbins JL, Zhai D, Cellitti J, et al. 2009. Apogossypol derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem. 52:4511–4523.
   PubMed Web of Science ®Google Scholar
• Wei J, Stebbins JL, Kitada S, Dash R, Zhai D, Placzek WJ, et al. 2011. An optically pure apogossypolone derivative as potent pan-active inhibitor of anti-apoptotic Bcl-2 family proteins. Front Oncol. 1:28.
   PubMedGoogle Scholar
• Wen Y, Meng Ws. 2014. Recent In Vivo Evidences of Particle-Based Delivery of Small-Interfering RNA (siRNA) into Solid Tumors. J Pharm Innov. 9:158–173.
   PubMed Web of Science ®Google Scholar
• Wolfrum C, Shi S, Jayaprakash KN, Jayaraman M, Wang G, Pandey RK, et al. 2007. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol. 25:1149–1157.
   PubMed Web of Science ®Google Scholar
• Yang B, Cai H, Qin W, Zhang B, Zhai C, Jiang B, Wu Y. 2013. Bcl-2-functionalized ultrasmall superparamagnetic iron oxide nanoparticles coated with amphiphilic polymer enhance the labeling efficiency of islets for detection by magnetic resonance imaging. Int J Nanomed. 8:3977–3990.
   PubMed Web of Science ®Google Scholar
• Yang Z-Z, Li J-Q, Wang Z-Z, Dong D-W, Qi X-R. 2014. Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas. Biomaterials. 35:5226–5239.
   PubMed Web of Science ®Google Scholar
• Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, Anderson DG. 2013. Non-viral vectors for gene-based therapy. Nat Rev Genet. 15:541–555.
   Web of Science ®Google Scholar
• Zhang S, Zhao B, Jiang H, Wang B, Ma B. 2007. Cationic lipids and polymers mediated vectors for delivery of siRNA. J Control Rel. 123:1–10.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Song T, Zhang T, Gao J, Wu G, An L, Du G. 2011. A novel BH3 mimetic S1 potently induces Bax/Bak‐dependent apoptosis by targeting both Bcl‐2 and Mcl‐1. Int J Cancer. 128:1724–1735.
   PubMed Web of Science ®Google Scholar
• Zheng C, Zheng M, Gong P, Deng J, Yi H, Zhang P, et al. 2013. Polypeptide cationic micelles mediated co-delivery of docetaxel and siRNA for synergistic tumor therapy. Biomaterials. 34:3431–3438.
   PubMed Web of Science ®Google Scholar